Defence Therapeutics Valuation
| DTCFF Stock | USD 0.41 0.00 0.00% |
Defence Therapeutics is overvalued. Defence Therapeutics shows a prevailing Real Value of $0.35 per share. The current price of the firm is $0.41. Our model computes the value of Defence Therapeutics from reviewing the firm fundamentals such as Shares Owned By Insiders of 5.26 %, price to book of 36.71 X, and Current Valuation of 60.32 M as well as analyzing its technical indicators and probability of bankruptcy. . In general, most investors advise locking in undervalued instruments and disposing overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Overvalued
Today
Please note that Defence Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Defence Therapeutics is based on 3 months time horizon. Increasing Defence Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Defence otc stock is determined by what a typical buyer is willing to pay for full or partial control of Defence Therapeutics. Since Defence Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Defence OTC Stock. However, Defence Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.41 | Real 0.35 | Hype 0.41 | Naive 0.41 |
The real value of Defence OTC Stock, also known as its intrinsic value, is the underlying worth of Defence Therapeutics OTC Stock, which is reflected in its stock price. It is based on Defence Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Defence Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Defence Therapeutics helps investors to forecast how Defence otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Defence Therapeutics more accurately as focusing exclusively on Defence Therapeutics' fundamentals will not take into account other important factors: Defence Therapeutics Total Value Analysis
Defence Therapeutics is currently forecasted to have takeover price of 60.32 M with market capitalization of 143.45 M, debt of , and cash on hands of 506.7 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Defence Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
60.32 M | 143.45 M | 506.7 K |
Defence Therapeutics Asset Utilization
One of the ways to look at asset utilization of Defence is to check how much profit was generated for every dollar of assets it reports. Defence Therapeutics shows a negative utilization of assets of -1.79 percent, losing $0.0179 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Defence Therapeutics shows how discouraging it operates for each dollar spent on its assets.Defence Therapeutics Ownership Allocation
Defence Therapeutics holds a total of 37.85 Million outstanding shares. Defence Therapeutics shows 5.26 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Defence Therapeutics Profitability Analysis
Net Loss for the year was (7.34 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Defence Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Defence Therapeutics and how it compares across the competition.
About Defence Therapeutics Valuation
The otc valuation mechanism determines Defence Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Defence Therapeutics. We calculate exposure to Defence Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Defence Therapeutics's related companies.Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biologicalbiosimilar therapeutic drugs for cancer and infectious diseases. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada. Defence Therapeutics is traded on OTC Exchange in the United States.
8 Steps to conduct Defence Therapeutics' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Defence Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Defence Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Defence Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Defence Therapeutics' revenue streams: Identify Defence Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Defence Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Defence Therapeutics' growth potential: Evaluate Defence Therapeutics' management, business model, and growth potential.
- Determine Defence Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Defence Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Defence Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Defence Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 36.6 M | |
| Retained Earnings | -10.5 M |
Complementary Tools for Defence OTC Stock analysis
When running Defence Therapeutics' price analysis, check to measure Defence Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Defence Therapeutics is operating at the current time. Most of Defence Therapeutics' value examination focuses on studying past and present price action to predict the probability of Defence Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Defence Therapeutics' price. Additionally, you may evaluate how the addition of Defence Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |